Stay updated on Ph 3 B-VEC Efficacy & Safety in DEB Clinical Trial
Sign up to get notified when there's something new on the Ph 3 B-VEC Efficacy & Safety in DEB Clinical Trial page.

Latest updates to the Ph 3 B-VEC Efficacy & Safety in DEB Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant updates, including a revision of the study model for the treatment of Dystrophic Epidermolysis Bullosa (DEB) and the removal of detailed participant criteria and study procedures. The revision number has also changed from v2.14.4 to v2.15.0.SummaryDifference28%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check87 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check94 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to Ph 3 B-VEC Efficacy & Safety in DEB Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ph 3 B-VEC Efficacy & Safety in DEB Clinical Trial page.